federal_register: 2022-25644
This data as json
| document_number | title | type | abstract | publication_date | pub_year | pub_month | html_url | pdf_url | agency_names | agency_ids | excerpts |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-25644 | Notice of Approval of Product Under Voucher: Rare Pediatric Disease Priority Review Voucher | Notice | The Food and Drug Administration (FDA) is announcing the issuance of approval of a product redeeming a priority review voucher. The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Food and Drug Administration Safety and Innovation Act (FDASIA), authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the issuance of priority review vouchers as well as the approval of products redeeming a priority review voucher. FDA has determined that the supplemental application for SKYRIZI (risankizumab-rzaa), approved June 16, 2022, meets the criteria for redeeming a priority review voucher. | 2022-11-25 | 2022 | 11 | https://www.federalregister.gov/documents/2022/11/25/2022-25644/notice-of-approval-of-product-under-voucher-rare-pediatric-disease-priority-review-voucher | https://www.govinfo.gov/content/pkg/FR-2022-11-25/pdf/2022-25644.pdf | Health and Human Services Department; Food and Drug Administration | 221,199 | The Food and Drug Administration (FDA) is announcing the issuance of approval of a product redeeming a priority review voucher. The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Food and Drug Administration Safety and Innovation... |